# Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination

> **NCT03455283** · — · COMPLETED · sponsor: **GE Healthcare** · enrollment: 2118 (actual)

## Conditions studied

- Magnetic Resonance Imaging (MRI)

## Interventions

- **DRUG:** Clariscan
- **OTHER:** Gadolinium-Based Contrast Agents

## Key facts

- **NCT ID:** NCT03455283
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-17
- **Primary completion:** 2019-11-11
- **Final completion:** 2019-11-11
- **Target enrollment:** 2118 (ACTUAL)
- **Last updated:** 2019-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455283, "Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03455283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*